Sponsored Links
| Response Biomedical Receives Decision Regarding CLIA Waiver For RAMP(R) NT-proBNP Assay For Diagnosis Of Heart Failure (HF) |
 |
 |
 |
| Medical News - Cardiovascular and Cardiology | |||
|
Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that it has received a notification from the U.S. Food and Drug Administration (FDA) that its NTproBNP Assay did not meet the criteria to obtain a waiver under the Clinical Laboratory Improvement Amendments of 1988 (CLIA)... Read more: Cardiovascular / Cardiology News From Medical News Today
|